Embryo Donation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Embryo donation is an assisted reproductive technology (ART) treatment in which embryos created by another couple during an IVF cycle — and subsequently donated when that couple has completed their family — are transferred to a recipient woman's uterus, where she carries the pregnancy to term. Embryo donation differs from IVF with own eggs in that the recipient has no genetic connection to the resulting child; the child is genetically related to the embryo donors (sperm and egg donors). Embryo donation is sometimes referred to as 'embryo adoption' — a term used particularly in the United States to reflect the altruistic, family-building nature of the process — though the legal framework in most countries regards it as a medical donation rather than an adoption.

The procedure begins with preparation of the recipient's uterine lining (endometrium) using hormonal medication — typically oestrogen followed by progesterone — to create a receptive environment for implantation. Once the endometrium reaches an adequate thickness (at least 7–8 mm) and structure (triple-line pattern on ultrasound), a frozen-thawed embryo is transferred to the uterus through a thin catheter inserted through the cervix without anaesthesia in a procedure taking 5–10 minutes. The transferred embryo most commonly consists of a blastocyst-stage embryo (day 5–6 after fertilisation) or, less commonly, a cleavage-stage embryo (day 3). The recipient then continues progesterone supplementation to support early pregnancy development until the placenta takes over hormone production at 8–10 weeks of pregnancy.

Embryos for donation come from IVF cycles in which couples have successfully completed their families and have consented to donate their cryopreserved surplus embryos to other couples. The embryos have typically undergone preimplantation genetic testing (PGT-A) in more recent years, improving per-transfer success rates. Donors undergo comprehensive medical, genetic, and psychological screening before donation is approved.

Embryo donation is indicated for couples and individuals for whom neither partner can contribute viable gametes for IVF. Primary indications include premature ovarian insufficiency (POI) where the woman has no remaining egg reserve and cannot produce eggs; repeated IVF failure with poor egg quality where egg donation has either failed or is not desired; severe male factor infertility where sperm donation alone is insufficient or declined; same-sex female couples who prefer embryo donation over egg donation with partner's sperm; single women without a male partner; and genetic conditions where both partners carry inheritable disorders making the use of their own gametes inadvisable.

Embryonic donation is also an option for women who have undergone premature surgical menopause (following bilateral oophorectomy for ovarian cancer, endometriosis, or hereditary risk reduction), women with primary amenorrhoea due to gonadal dysgenesis (Turner syndrome), and cancer survivors who did not preserve eggs or embryos before gonadotoxic cancer treatment. In some cases, embryo donation is chosen by couples who have experienced multiple failed IVF cycles with genetically normal embryos where implantation failure is suspected but cannot be corrected — donated embryos with known prior implantation success may be preferred.

Recipients of donated embryos must have a structurally normal, functionally receptive uterus. This is assessed by baseline ultrasound, hysteroscopy (inspection of the uterine cavity), and sometimes sonohysterography or saline infusion sonogram to exclude uterine polyps, fibroids, adhesions, or congenital anomalies that could impair embryo implantation. A functional endometrium — able to respond to oestrogen and progesterone stimulation — is required, though even women with surgical menopause or ovarian failure retain endometrial function responsive to exogenous hormones in most cases. Upper age limits for embryo donation recipients vary by country and centre: most IVF clinics in India and Thailand accept recipients up to 45–50 years; UK NHS treatment is funded to age 42; in the US, many private clinics treat recipients up to 50–55 with personalised counselling.

Psychological counselling and assessment of the recipient(s) and their partner is mandatory before embryo donation treatment begins, covering the implications of raising a child with no genetic connection to either parent, how and when to disclose donor conception to the child, and support resources. Medical screening of recipients includes general health assessment, reproductive organ imaging, infectious disease testing (HIV, hepatitis B and C, syphilis), chromosomal karyotype in some centres, and uterine cavity assessment. Recipients with significant systemic medical conditions (uncontrolled hypertension, severe diabetes, cardiac disease) may require additional medical clearance or stabilisation before proceeding.

Embryo transfer can be performed in a natural cycle (for women with regular menstrual cycles and predictable ovulation) or a hormonally prepared (artificial) cycle. Natural cycle transfer uses monitoring of the recipient's natural LH surge and ovulation to time the transfer appropriately; it requires no hormonal medication beyond luteal phase progesterone support, but requires closer monitoring and carries a risk of cycle cancellation if ovulation is poorly timed. Artificial (programmed) cycle preparation using exogenous oestradiol (oral, transdermal patch, or vaginal tablets) followed by progesterone supplementation is the preferred approach in most recipients, particularly those without natural ovarian function, as it offers complete control over the timing of endometrial preparation and transfer scheduling.

Most embryo donation transfers use cryopreserved (frozen) embryos — typically high-quality blastocysts graded according to the Gardner blastocyst grading scale. Modern vitrification (ultra-rapid freezing) technology has dramatically improved frozen embryo survival rates (greater than 95% for well-vitrified embryos) and clinical outcomes, with freeze-all policies now yielding outcomes equivalent to or better than fresh transfers. Some centres offer simultaneous or sequential transfer of two embryos to increase success rates, though single embryo transfer (SET) is increasingly recommended globally to minimise twin pregnancy risks. Preimplantation genetic testing for aneuploidies (PGT-A) on donated embryos, where available, selects euploid embryos for transfer, significantly improving per-transfer success rates.

Embryo donation offers several meaningful clinical advantages. Success rates per transfer are generally higher than IVF with own eggs in older women or women with poor egg quality, because donated embryos come from younger donors or from couples with documented implantation success — the embryos have already demonstrated developmental competence by surviving cryopreservation. Clinical pregnancy rates per frozen embryo transfer are typically 40–60% per cycle at experienced centres, with live birth rates of 30–50% per transfer — favourably comparable to IVF outcomes in younger women with good prognosis. For recipients with POI or surgical menopause in their 30s–40s, embryo donation offers pregnancy rates substantially higher than would be achievable with own eggs.

A profound advantage of embryo donation over egg donation is that both genetic contributors (the embryo donors) have been screened, are consented, and the embryo has already been created — recipients avoid the emotional and physical complexity of fresh egg donation cycles requiring synchronisation with a donor's ovarian stimulation. The recipient's experience is entirely that of a gestational pregnancy: she nurtures the pregnancy, carries the child to term, and if breastfeeding is desired, can often stimulate lactation. Recipient parents report high satisfaction with embryo donation, and studies show that children born from donated embryos develop equally well psychologically, socially, and educationally as children conceived naturally, with age-appropriate disclosure of donor conception recommended.

Embryo transfer itself carries minimal direct procedural risk — it is performed without anaesthesia through the cervix and is comparable in discomfort to a cervical smear test. Rare complications include uterine cramping (which may be significant in women with adenomyosis or retroflexed uteri), vasovagal reactions during cervical passage, and very rarely, uterine perforation (less than 0.1%). Progesterone supplementation side effects include bloating, breast tenderness, vaginal discharge (with vaginal progesterone), drowsiness (with oral progesterone), and minor skin reactions (with injectable progesterone). Ovarian hyperstimulation syndrome (OHSS) does not occur in recipients as they are not undergoing ovarian stimulation.

Pregnancy complications in embryo donation recipients include similar obstetric risks to IVF pregnancies generally: slightly elevated rates of pre-eclampsia compared to spontaneous conception, particularly in oocyte donation recipients (possibly related to the immunological challenge of a fully non-self placenta), higher rates of low birthweight, preterm birth, and perinatal complications compared to naturally conceived singletons. Twin pregnancy risks — prematurity, growth restriction, neonatal intensive care — are significantly higher than singleton risks and are the primary argument for single embryo transfer policy. Recipient mothers carry an adjusted risk of pre-eclampsia approximately 3-fold higher than in natural conception across multiple studies.

Following embryo transfer, the recipient continues progesterone supplementation (and oestrogen if in an artificial cycle) and rests for the remainder of the transfer day. A serum beta-hCG (pregnancy test) is performed 10–14 days after transfer to detect implantation. A rising hCG level confirming pregnancy is followed by an early pregnancy ultrasound at 6–7 weeks to confirm intrauterine location, fetal heartbeat, and number of gestational sacs. If the cycle results in a positive pregnancy, hormonal supplementation is continued until 8–12 weeks of gestation, when the placenta assumes hormone production.

Obstetric care for embryo donation pregnancies should be coordinated with the recipient's obstetrician, ideally one experienced with ART pregnancies. Recipients with ovarian failure are at higher risk of pre-eclampsia and should be referred to high-risk obstetric services early. Psychological support throughout the treatment process and into pregnancy and parenthood is important for all embryo donation recipients. Post-pregnancy counselling regarding disclosure of donor conception to the child — recommended by professional bodies worldwide — and access to donor conception support groups should be provided. Failed transfer cycles are reviewed with the fertility specialist to optimise endometrial preparation and consider PGT-A for remaining embryos.

Embryo donation costs include recipient medical screening, medication for endometrial preparation, the embryo transfer procedure, embryo storage fees, and psychological counselling. In the US, embryo donation costs range from USD 5,000–15,000 for a complete cycle including medications, clinic fees, and embryo matching/donation fees; some clinics charge separate 'embryo adoption' programme fees. In the UK, HFEA-licensed embryo donation is available through NHS and private clinics, with private cycle costs of GBP 3,000–6,000. These costs are lower than IVF with fresh egg donation (USD 25,000–40,000 in the US) as no donor stimulation, egg retrieval, or fresh cycle costs are involved.

For patients accessing embryo donation internationally, India offers a cost-effective destination with ICMR-regulated fertility clinics. A complete embryo donation cycle in India costs approximately USD 2,000–4,500, including all medications, ultrasound monitoring, embryo transfer, and first-trimester follow-up. This represents savings of 50–70% versus US prices. Thailand (Bangkok) and Spain (Barcelona, Madrid) are also popular destinations for embryo donation, with Spain offering the largest egg and embryo donation programmes in Europe due to well-established legal frameworks and extensive donor registries. Patients considering international embryo donation should confirm the legal status of donor conception in both the treatment country and their country of residence.

For couples where one partner can contribute genetically, egg donation (using donor eggs with the male partner's sperm) or sperm donation (using donor sperm with the female partner's eggs) are preferable alternatives that maintain a partial genetic connection to the child. For couples who prioritise a genetic connection, preimplantation genetic diagnosis (PGD) combined with IVF using own gametes, where technically and legally feasible, may allow selection of unaffected embryos even when both parents carry genetic conditions.

Adoption — legal adoption of a child born to another family — is an alternative path to parenthood that does not involve pregnancy but may be available and appropriate for couples or individuals for whom pregnancy is medically inadvisable or personally undesired. Child-free living, when reached through a process of grief, support, and reflection, is a valid life choice for couples unable to achieve parenthood through fertility treatment or adoption. Surrogacy — in which a gestational carrier carries an embryo for intended parents — is an alternative where the intended mother cannot carry a pregnancy but may be able to produce eggs (or uses donor eggs).

For women with POI who retain some residual ovarian function (rare cases), extremely stimulation protocols or natural cycle IVF may yield occasional own eggs. Experimental approaches including ovarian tissue transplantation (autologous or allografted) are available in specialist centres for specific patient groups such as cancer survivors.